AND-gated Synthetic Biomarkers for Early Detection of Liver Metastasis
用于早期检测肝转移的 AND 门控合成生物标志物
基本信息
- 批准号:10685432
- 负责人:
- 金额:$ 59.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-23 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AmplifiersBacteriaBar CodesBenchmarkingBiodistributionBiologicalBiological MarkersBiologyBiosensorBloodBlood TestsBody FluidsCancer BiologyCancer DiagnosticsCancerousCarcinoembryonic AntigenCellsClassificationColorectal CancerComplexCoupledCyclic PeptidesDataDetectionDevelopmentDiagnosticDiseaseDrug KineticsEarly DiagnosisEnzymesExcisionFDA approvedFluorogenic SubstrateFutureGene ExpressionGenesGeneticGenetic EngineeringGenetic TranscriptionGrowthHumanHydrolysisImageIn SituInbred BALB C MiceKineticsLS174T colon cancer cell lineLiverLogicLongitudinal StudiesMalignant NeoplasmsMammalian CellMass Spectrum AnalysisMetastatic Neoplasm to the LiverModelingMolecularMonitorNeoplasm MetastasisNoiseNon-Invasive DetectionPatient-Focused OutcomesPeptide FragmentsPeptide HydrolasesPeptidesPerformancePlayPreclinical TestingProductionProteinsRecombinantsReporterRoleSafetySamplingScreening for cancerSerumShapesSignal TransductionSiteSpecificityT cell responseT cell therapyTestingThermal Ablation TherapyTissuesTumor AntigensUrineValidationXenograft ModelXenograft procedureantigen testcandidate identificationclinically relevantcolorectal cancer screeningdesigndetection limitdifferential expressionearly detection biomarkersengineered T cellsfluorophoreimmunogenicityimprovedin vivoiron oxide nanoparticlemathematical modelmicroCTmodels and simulationmouse modelneoplastic cellpre-clinicalpreclinical evaluationpredictive modelingradiological imagingsensorsynthetic biologysystemic toxicitytumortumor specificityvalidation studies
项目摘要
PROJECT SUMMARY
Advances in synthetic biology will play a fundamental role in shaping the future of cancer diagnostics toward
earlier and more specific detection of disease. For example, whole-cell biosensors such as bacteria have been
genetically engineered to perform complex functions such as signal amplification to detect clinically relevant
biomarkers in human urine and serum. In mammalian cells, sense-and-respond components that employ
Boolean logic have been demonstrated for multiplexed control of engineered T cell therapies, thereby increasing
the specificity of tumor sensing and reducing systemic toxicity. These advances highlight the promise of synthetic
biology when applied to cancer, yet the vast majority of these strategies rely on genetic circuits and make use of
non-mammalian protein components. Such circuits are complex and raise safety and immunogenicity concerns
for regulatory approval, especially in the context of in vivo early cancer detection where repeated administrations
of biosensors are likely needed to monitor for nascent disease. This proposal seeks to develop a new class of
diagnostics called AND-gated synthetic biomarkers for early detection of cancer metastasis. Synthetic
biomarkers are an emerging class of activatable biological sensors that are designed to be administered
systemically, query sites of early disease, and harness tumor-dependent activation mechanisms, such as
dysregulated protease activity, to drive production of a reporter. These reporters can then be detected
noninvasively from blood, urine, or other bodily fluid samples. Proteases play key biological roles across the
major hallmarks of metastasis and are particularly potent molecular amplifiers by catalyzing the irreversible
hydrolysis of peptide bonds, allowing a single protease to turnover thousands of substrates. AND-gated synthetic
biomarkers will be applied for early detection of colorectal cancer (CRC) liver metastasis. Although the liver is a
common site for metastatic spread from primary CRC, regional resection of liver-isolated metastases can lead
to potentially curative results. Yet early detection of CRC liver metastases at a size when they are most
responsive to therapy (1–2 mm) remains challenging by radiographic imaging such as CT and FDA-approved
blood test such as the carcinoembryonic antigen (CEA) test. To design AND-gated synthetic biomarkers for CRC
liver metastasis, pairwise combinations of proteases will be selected based on differential RNA expression in
CRC liver metastases compared to healthy liver tissue. Multivariate mathematical models will be developed to
understand how design parameters enhance specificity and cooperativity compared to experimental results.
Syngeneic and xenograft models of CRC liver metastasis will be used for preclinical validation studies to allow
benchmarking against CT and CEA. This proposal will lay the groundwork for earlier detection of cancer
metastasis by programmable synthetic biomarkers.
项目概要
合成生物学的进步将在塑造癌症诊断的未来方面发挥基础性作用
例如,细菌等全细胞生物传感器已被广泛应用。
经过基因工程改造以执行复杂的功能,例如信号放大以检测临床相关
人类尿液和血清中的生物标志物在哺乳动物细胞中,利用这些成分进行感知和响应。
布尔逻辑已被证明可用于工程 T 细胞疗法的多重控制,从而增加
肿瘤传感的特异性和降低全身毒性这些都凸显了合成的前景。
生物学应用于癌症时,但绝大多数这些策略依赖于遗传电路并利用
这种电路很复杂,引起了安全性和免疫原性问题。
获得监管批准,特别是在体内早期癌症检测的情况下,重复给药
可能需要大量生物传感器来监测新生疾病。该提案旨在开发一类新的传感器。
称为 AND 门控合成生物标志物的诊断方法,用于早期检测癌症合成转移。
生物标记物是一类新兴的可激活生物传感器,旨在进行管理
系统地查询早期疾病的位点,并利用肿瘤依赖性激活机制,例如
失调的蛋白酶活性,驱动报告基因的产生,然后可以检测到这些报告基因。
无创地从血液、尿液或其他体液样本中提取蛋白酶在整个过程中发挥着关键的生物学作用。
转移的主要标志,并且是通过催化不可逆转的特别有效的分子放大器
肽键的水解,允许单个蛋白酶转换数千个“与”门控的合成底物。
生物标志物将用于结直肠癌(CRC)肝转移的早期检测。
原发性 CRC 转移扩散的常见部位,肝隔离转移灶的区域切除可导致
早期发现结直肠癌肝转移,以达到潜在的治愈效果。
通过放射成像(例如 CT 和 FDA 批准的)对治疗的反应(1-2 毫米)仍然具有挑战性
血液测试,例如癌胚抗原 (CEA) 测试 设计用于 CRC 的 AND 门控合成生物标志物。
肝转移中,将根据差异RNA表达来选择蛋白酶的成对组合
将开发 CRC 肝转移与健康肝组织的多变量数学模型。
与实验结果相比,了解设计参数如何增强特异性和协同性。
CRC肝转移的同基因和异种移植模型将用于临床前验证研究,以允许
该提案将为癌症的早期检测奠定基础。
通过可编程合成生物标志物进行转移。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Embracing enzyme promiscuity with activity-based compressed biosensing.
通过基于活性的压缩生物传感拥抱酶混杂。
- DOI:
- 发表时间:2023-01-23
- 期刊:
- 影响因子:0
- 作者:Holt, Brandon Alexander;Lim, Hong Seo;Sivakumar, Anirudh;Phuengkham, Hathaichanok;Su, Melanie;Tuttle, McKenzie;Xu, Yilin;Liakakos, Haley;Qiu, Peng;Kwong, Gabriel A
- 通讯作者:Kwong, Gabriel A
Gene representation in scRNA-seq is correlated with common motifs at the 3' end of transcripts.
scRNA-seq 中的基因表示与转录本 3 端的常见基序相关。
- DOI:
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Li, Xinling;Gibson, Greg;Qiu, Peng
- 通讯作者:Qiu, Peng
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gabriel A Kwong其他文献
Gabriel A Kwong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gabriel A Kwong', 18)}}的其他基金
Bioinspired nanovectors for CRISPR/Cas9-mediated CAR T cell manufacturing
用于 CRISPR/Cas9 介导的 CAR T 细胞制造的仿生纳米载体
- 批准号:
10373260 - 财政年份:2022
- 资助金额:
$ 59.28万 - 项目类别:
DNA-gated cytometry for multiplexed sorting of antigen-specific CD8 T cells
用于抗原特异性 CD8 T 细胞多重分选的 DNA 门控细胞术
- 批准号:
10503181 - 财政年份:2022
- 资助金额:
$ 59.28万 - 项目类别:
Finding Sleeping Beauty: T Cell Biosensors for Dormant Cancer Detection
寻找睡美人:用于检测休眠癌症的 T 细胞生物传感器
- 批准号:
10707371 - 财政年份:2022
- 资助金额:
$ 59.28万 - 项目类别:
Finding Sleeping Beauty: T Cell Biosensors for Dormant Cancer Detection
寻找睡美人:用于检测休眠癌症的 T 细胞生物传感器
- 批准号:
10487754 - 财政年份:2022
- 资助金额:
$ 59.28万 - 项目类别:
DNA-gated cytometry for multiplexed sorting of antigen-specific CD8 T cells
用于抗原特异性 CD8 T 细胞多重分选的 DNA 门控细胞术
- 批准号:
10650429 - 财政年份:2022
- 资助金额:
$ 59.28万 - 项目类别:
Bioinspired nanovectors for CRISPR/Cas9-mediated CAR T cell manufacturing
用于 CRISPR/Cas9 介导的 CAR T 细胞制造的仿生纳米载体
- 批准号:
10563185 - 财政年份:2022
- 资助金额:
$ 59.28万 - 项目类别:
AND-gated Synthetic Biomarkers for Early Detection of Liver Metastasis
用于早期检测肝转移的 AND 门控合成生物标志物
- 批准号:
10493339 - 财政年份:2021
- 资助金额:
$ 59.28万 - 项目类别:
AND-gated Synthetic Biomarkers for Early Detection of Liver Metastasis
用于早期检测肝转移的 AND 门控合成生物标志物
- 批准号:
10330265 - 财政年份:2021
- 资助金额:
$ 59.28万 - 项目类别:
Harnessing protease activity for predictive monitoring of cancer immunotherapy
利用蛋白酶活性进行癌症免疫治疗的预测监测
- 批准号:
10348165 - 财政年份:2019
- 资助金额:
$ 59.28万 - 项目类别:
Harnessing protease activity for predictive monitoring of cancer immunotherapy
利用蛋白酶活性进行癌症免疫治疗的预测监测
- 批准号:
9897497 - 财政年份:2019
- 资助金额:
$ 59.28万 - 项目类别:
相似国自然基金
海洋细菌Halomonas sp. D47裂解二甲基巯基丙酸内盐(DMSP)释放环境效应气体二甲基硫(DMS)的代谢调控过程与机制
- 批准号:32370136
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
细菌响应性抗菌抗炎复合温敏水凝胶促进皮肤恶性肿瘤术后创面快速愈合的作用与机制研究
- 批准号:82372519
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
新型细菌色氨酸羟化酶家族的酶学表征、生化机理与应用研究
- 批准号:32370051
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
草地贪夜蛾共生细菌Enterococcus casseliflavus来源的色氨酸介导宿主氯虫苯甲酰胺解毒代谢机制
- 批准号:32302393
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
“持续化学发光与多效抗菌”复合探针的构筑及其关节假体周围感染细菌的检测与灭活研究
- 批准号:82302646
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
AND-gated Synthetic Biomarkers for Early Detection of Liver Metastasis
用于早期检测肝转移的 AND 门控合成生物标志物
- 批准号:
10493339 - 财政年份:2021
- 资助金额:
$ 59.28万 - 项目类别:
AND-gated Synthetic Biomarkers for Early Detection of Liver Metastasis
用于早期检测肝转移的 AND 门控合成生物标志物
- 批准号:
10330265 - 财政年份:2021
- 资助金额:
$ 59.28万 - 项目类别:
Dynamics of Pseudomonas aeruginosa During Bacteremia
菌血症期间铜绿假单胞菌的动态
- 批准号:
10042352 - 财政年份:2020
- 资助金额:
$ 59.28万 - 项目类别:
Dynamics of Pseudomonas aeruginosa During Bacteremia
菌血症期间铜绿假单胞菌的动态
- 批准号:
10042352 - 财政年份:2020
- 资助金额:
$ 59.28万 - 项目类别:
Dynamics of Pseudomonas aeruginosa During Bacteremia
菌血症期间铜绿假单胞菌的动态
- 批准号:
10222524 - 财政年份:2020
- 资助金额:
$ 59.28万 - 项目类别: